News for Chugai Pharmaceutical Co., Ltd. (4519.T)

Chugai Pharmaceutical Co Ltd (TSE:4519) is set to release its Q2 2025 earnings on Jul 24, 2025. The consensus estimate for Q2 2025 revenue is $326.77 billion, a

Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platformAccelerating the creation of innovation by combining Gero's aging-focused target discovery technology with Chugai's drug discovery technologies TOKYO, July 07, 2025 (GLOBE NEWSWIRE) -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter 'Chugai'), and Gero PTE. LTD. (hereafter 'Gero'), a Singapore-based biotechnology company, announced today that they have entered into a joint research and license agreement to develop novel therapies for age-related diseases.

- Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - N

PR NewswireINDIANAPOLIS, May 29, 2025 INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies o

- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Cali

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates

**media[606500]**

Apr 24, 2025 / 09:00AM GMTPresentationApr 24, 2025 / 09:00AM GMT =====================Corporate Participants===================== * Kae Miyata Chugai Ph

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA), a clinical-stage company developing transformative therapies for the treatmen

PR NewswireINDIANAPOLIS, April 17, 2025 Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average

Exploring the Strategic Moves of T. Rowe Price Japan Fund (Trades, Portfolio) in Q1 2025 T. Rowe Price Japan Fund (Trades, Portfolio) recently submitted its N-

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

**media[592008]**

**media[558065]**

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expecte

New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo …

https://mms.businesswire.com/media/20250213843444/en/2382130/19/GALDERMA_BERLIN_2025_INTERVIEW_YOUTUBE_V4.mp4 Ad hoc announcement pursuant to Art. 53 LR

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ETCompany ParticipantsKae Miyata - Head of Corporate...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd.